Recommendations for observational studies of comorbidity in multiple sclerosis
Authors:
- Ruth Ann MarrieRMRuth Ann Marrie
- Aaron MillerAMAaron Miller
- Maria Pia SormaniMSMaria Pia Sormani
- Alan ThompsonATAlan Thompson
- Emmanuelle WaubantEWEmmanuelle Waubant
- Maria TrojanoMTMaria Trojano
- Paul O'ConnorPOPaul O'Connor
- Kirsten FiestKFKirsten Fiest
- Nadia ReiderNRNadia Reider
- Stephen ReingoldSRStephen Reingold
- Jeffrey A. CohenJCJeffrey A. Cohen
- For the attendees of the International Workshop on Comorbidity in Multiple SclerosisFSFor the attendees of the International Workshop on Comorbidity in Multiple Sclerosis
Open Access
- 12 April 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (15) , 1446-1453
Abstract
Objective: To reach consensus about the most relevant comorbidities to study in multiple sclerosis (MS) with respect to incidence, prevalence, and effect on outcomes; review datasets that may support studies of comorbidity in MS; and identify MS outcomes that should be prioritized in such studies. Methods: We held an international workshop to meet these objectives, informed by a systematic review of the incidence and prevalence of comorbidity in MS, and an international survey regarding research priorities for comorbidity. Results: We recommend establishing age- and sex-specific incidence and prevalence estimates for 5 comorbidities (depression, anxiety, hypertension, hyperlipidemia, and diabetes); evaluating the effect of 7 comorbidities (depression, anxiety, hypertension, diabetes, hyperlipidemia, chronic lung disease, and autoimmune diseases) on disability, quality of life, brain atrophy and other imaging parameters, health care utilization, employment, and mortality, including age, sex, race/ethnicity, socioeconomic status, and disease duration as potential confounders; harmonizing study designs across jurisdictions; and conducting such studies worldwide. Ultimately, clinical trials of treating comorbidity in MS are needed. Conclusion: Our recommendations will help address knowledge gaps regarding the incidence, prevalence, and effect of comorbidity on outcomes in MS.Keywords
This publication has 61 references indexed in Scilit:
- Milder multiple sclerosis course in patients with concomitant inflammatory bowel diseaseMultiple Sclerosis Journal, 2013
- Smoking: effects on multiple sclerosis susceptibility and disease progressionTherapeutic Advances in Neurological Disorders, 2011
- Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosisJournal of Neuroinflammation, 2011
- Association between comorbidity and clinical characteristics of MSActa Neurologica Scandinavica, 2010
- Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS courseThe Journal of Headache and Pain, 2010
- Vascular comorbidity is associated with more rapid disability progression in multiple sclerosisNeurology, 2010
- Defining Comorbidity: Implications for Understanding Health and Health ServicesThe Annals of Family Medicine, 2009
- Smoking and Disease Progression in Multiple SclerosisArchives of Neurology, 2009
- Comorbidity delays diagnosis and increases disability at diagnosis in MSNeurology, 2009
- A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherenceJournal of Neurology, Neurosurgery & Psychiatry, 2007